Adneuris Therapeutics, a wholly-owned subsidiary of Tris Pharma advancing a new kind of pain medicine, announced that it has ...
German science and technology group Merck KGaA (MRK: DE) has upgraded its full-year outlook after a second quarter in which its laboratory and semiconductor materials businesses more than covered a ...
There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted ...
Cambridge, USA-based mRNA vaccines company Moderna announced that the US Food and Drug Administration (FDA) has approved ...
For decades, the pharmaceutical industry has largely focused on discovering new molecules. Laxxon Medical believes the next ...
US biotech Amgen reported a 10% increase in second-quarter 2026 revenue, as growth from Repatha (evolocumab), Evenity ...
US drugmaker Gilead Sciences raised the lower end of its 2026 sales guidance after second-quarter revenue beat expectations, driven by continued growth in HIV and oncology.
USA-based biotech major Amgen (Nasdaq: AMGN) has disclosed what it called a material cybersecurity incident, in which hackers ...
Swiss affordable medicines company Sandoz today presented its financial results for the first half of 2026 and net-sales ...
The US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with ...
US pharma major Merck & Co (NYSE: MRK), known as MSD outside the USA and Canada, reported second-quarter sales of $16.61 billion, up 5% year on year and 4% excluding currency, but a one-time charge ...
UK and USA-based biotech Tiziana Life Sciences has announced quantitative PET imaging results from the third patient with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results